With the recent discovery of JAK2 mutations in myeloproliferative disorders, medical science has taken a revolutionary stride forward toward understanding the pathogenesis of these diseases. This new advancement translates not only to a more rapid and reliable diagnosis, but also allows groundbreaking research into the development of new therapeutics. Written in an easy-to-follow text "myeloproliferative disorders "gives the practicing clinician a single source answer to classification, diagnosis, management, and recent advances in this disorder.